ImmunityBio, Inc.
Gemcitabine
Platinum-resistant Ovarian Cancer
Countdown
328days
Phase 2 readout · ~ May 31, 2027 estimated
What's at stake
Phase 2 trial results for Gemcitabine in Platinum-resistant Ovarian Cancer are due ~ May 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 14h ago
“CT.gov NCT06710288: Phase 2 trial, sponsor ImmunityBio, Inc., drug Gemcitabine. Primary completion date 2027-05 (estimated).”